Paclitaxel (Taxol)

Paclitaxel, also known by the brand name Taxol, has been successfully used to treat a variety of cancers. However, the chemotherapeutic drug has received mixed reviews for treating mesothelioma. Paclitaxel is most effective when used as part of a multimodal treatment plan.

Written By

Edited By

This page features: 11 cited research articles

Paclitaxel (Taxol) is approved by the Food and Drug Administration (FDA) for use against breast cancer, non-small cell lung cancer and ovarian cancer.

Despite the drug’s success in treating these cancers, past clinical trials in mesothelioma patients have had less than ideal outcomes, with most patients experiencing no benefits. Doctors believe paclitaxel, like cisplatin and carboplatin, will work best when combined with other treatments such as surgery, radiation therapy and other chemotherapy drugs.

Discovery and History of Paclitaxel

This promising drug dates back to the late 1960s, when it was discovered in the bark of the Pacific yew tree. Its potential as an anti-cancer agent was immediately recognized, but its natural scarcity made it difficult to market. More than 20 years later, researchers were finally able to synthetically produce it. That same year, Bristol-Myers Squibb began marketing Taxol.

How and When is Paclitaxel Used?

A doctor or nurse may inject paclitaxel into a vein or give it via a three-hour intravenous drip. Both treatments are administered once every three weeks.

For mesothelioma, this drug may be used in conjunction with other chemotherapy drugs such as cisplatin or carboplatin. In these cases, the patient usually receives both chemotherapy drugs intravenously on the same day.

Paclitaxel is known as an antimicrotubule agent. Once inside the body, it binds to proteins in microtubules, which are necessary for cell division, and blocks their functions.

This forces the cells to stop dividing, which eventually kills them. Since mesothelioma cancer cells rapidly divide and spread, their microtubules are a logical target.

Drug Fast Facts

Paclitaxel Information




Bristol-Myers Squibb

Medical Code

J9264, J9265, J9267


135 mg/m² every three weeks

Administration Route


Active Ingredient


Drug Class

Antineoplastic vinca alkaloid

Alternate Names

Abraxane, Anzatax, Asotax, Bristaxol, Onxol, Praxel, Taxol Konzentrat

Interacting Drug

Flu vaccine, St. John’s wort, doxorubicin, bevacizumab, clarithromycin, quercetin, ifosfamine, eluxadoline, idarubicin, idelalisib, ivacaftor, nefazodone, palifermin, quinidine

Medical Studies

A Phase I Study of the Mesothelin-Targeted Immunotoxin LMB-100 with or Without Nab-Paclitaxel (Abraxane) in Patients with Malignant Mesothelioma

FDA Warning

Bone marrow suppression, allergic reactions, sever conduction abnormalities in patients with a pacemaker, fetal harm

Get the Best Treatment

Get help connecting with the nation's top mesothelioma doctors and cancer centers.

Get Help Now

What are the Side Effects of Paclitaxel?

Like any chemotherapy agent, paclitaxel may damage healthy cells in addition to cancer cells. This can result in side effects such as nausea, hair loss, mouth sores and fatigue. Rare, but dangerous side effects include numbness in the extremities, excessive fatigue, chest pain or slowed heartbeat.

Study Results of Paclitaxel in Mesothelioma Patients

Based on its success in treating patients with other types of cancer, doctors believe paclitaxel will eventually have a practical use in mesothelioma patients as well. However, its efficacy in treating mesothelioma remains questionable. Early studies in the late 1990s showed no improvements in life span.

The trials in the ’90s tested the drug as a single agent, meaning no other cancer treatments were given during the clinical trials. These tests showed no improvements. A 1996 study reported a median survival time of nine months, and a similar 1999 study reported a median survival of five months.

Despite less-than-hopeful clinical trial results in the past, doctors are still optimistic about the future role of paclitaxel in the treatment of mesothelioma. They continue to study the drug to find new ways of using it to treat mesothelioma patients. For example, a recent Phase II study, for which results are not yet available, focused on administering the drug in combination with surgery and heated chemotherapy.

Free VA Claims Assistance

Get Help Now

Qualify for Free Medical Care

See If You Qualify

Get Help Paying for Treatment

Learn More

Get Free VA Claims Assistance

Qualify for Free Medical Care

Get Help Paying for Treatment

Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?

Karen Selby joined in 2009. She is a registered nurse with a background in oncology and thoracic surgery and was the director of a tissue bank before becoming a Patient Advocate at The Mesothelioma Center. Karen has assisted surgeons with thoracic surgeries such as lung resections, lung transplants, pneumonectomies, pleurectomies and wedge resections. She is also a member of the Academy of Oncology Nurse & Patient Navigators.

Last Modified February 8, 2018
  1. Bristol-Myers Squibb (2011). Products. Retrieved from
  2. Chemocare (2011). Chemotherapy Drugs: Paclitaxel. Retrieved from
  3. Genentech (2011). Product Information: Avastin. Retrieved from
  4. Hughes, M.S. (2011). Treatment of Peritoneal Cancer with Surgery, Perfused Heated Cisplatin and Chemotherapy [Clinical Trial]. National Institutes of Health Clinical Center. Retrieved from
  5. Medline Plus (2011). Paclitaxel Injection. Retrieved from
  6. National Cancer Institute (2011). Cancer Drug Information: Paclitaxel. Retrieved from
  7. National Cancer Institute (2011). NCI Drug Dictionary: Paclitaxel. Retrieved from
  8. Stephenson, F. (2002). A Tale of Taxol. Florida State University. Retrieved from
  9. U.S. Environmental Protection Agency (2004). 2004 Greener Synthetic Pathways Award: Bristol-Myers Squibb Company. Retrieved from
  10. Van Meerbeeck, J., et al (1996). Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. British Journal of Cancer, 74, 961-963. Retrieved from
  11. Vogelzang, N.J., et al (1999). High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234. Annals of Oncology, 10, 597-600. Retrieved from

View our resources for patients and families

Get Help Today
Chat live with a patient advocate now loading spinner